Merck KGaA returns rights to Apitope's vaccine

Apitope International N.V. (Diepenbeek, Belgium) said Merck KGaA (Xetra:MRK) returned global rights to multiple sclerosis candidate ATX-MS-1467. Apitope did not disclose a reason for why Merck KGaA handed back the molecule. This quarter, Apitope expects data from a Phase IIa trial of the candidate to treat relapsing MS. It is a vaccine containing four synthetic peptides derived from human myelin basic protein. ...